<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631577</url>
  </required_header>
  <id_info>
    <org_study_id>BO29562</org_study_id>
    <secondary_id>2015-002467-42</secondary_id>
    <nct_id>NCT02631577</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma</brief_title>
  <official_title>A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH OBINUTUZUMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, efficacy, pharmacokinetics and immunogenicity of
      induction treatment consisting of atezolizumab in combination with obinutuzumab plus
      lenalidomide in patients with relapsed or refractory follicular lymphoma (FL), followed by
      maintenance treatment with atezolizumab plus obinutzumab plus lenalidomide in patients who
      achieve a complete response (CR), a partial response (PR), or stable disease at end of
      induction.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 31, 2015</start_date>
  <completion_date type="Anticipated">March 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs) during cycle 2 of study treatment</measure>
    <time_frame>Day 1- Day 28 of second cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving CR at EOI, as Determined by the Independent Review Committee (IRC) Using Lugano Criteria</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events and Serious Adverse Events</measure>
    <time_frame>30 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving CR at EOI, as Determined by the Investigator Using Lugano Criteria</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving CR at EOI, as Determined by the IRC and Investigator Using Modified Cheson Criteria</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response (CR or PR) at EOI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response (CR or PR) During the Study</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Lymphoma, Follicular</condition>
  <arm_group>
    <arm_group_label>Atezolizumab-G-lena</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation phase: Participants with relapsed or refractory FL will receive obinutuzumab (G) and lenalidomide (lena) during Cycle 1 (28-day cycle) and atezolizumab (MPDL3280A), obinutuzumab, and lenalidomide during Cycles 2-6, during induction treatment, followed by atezolizumab (MPDL3280A; monthly) and obinutuzumab (every other month [q2m]) for 24 months as well as lenalidomide for 12 months, during maintenance treatment. Expansion phase: Participants with previously untreated FL will receive same treatment regimen as described for dose escalation phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab (MPDL3280A) [TECENTRIQ]</intervention_name>
    <description>Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.</description>
    <arm_group_label>Atezolizumab-G-lena</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.</description>
    <arm_group_label>Atezolizumab-G-lena</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.</description>
    <arm_group_label>Atezolizumab-G-lena</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

          -  Relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy
             regimen that included an anti-CD20 monoclonal antibody and for which no other more
             appropriate treatment option exists as determined by the investigator

          -  Histologically documented CD20-positive lymphoma as determined by the local laboratory

          -  Fluorodeoxyglucose-avid lymphoma (i.e., PET-positive lymphoma)

          -  At least one bi-dimensionally measurable lesion (&gt;1.5 cm in its largest dimension by
             CT scan or magnetic resonance imaging [MRI])

          -  Availability of a representative tumor specimen and the corresponding pathology report
             for retrospective central confirmation of the diagnosis of FL

          -  Agreement to comply with all local requirements of the lenalidomide risk minimization
             plan

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use two adequate methods of contraception, including at
             least one method with a failure rate of &lt;1% per year, for at least 28 days prior to
             Day 1 of Cycle 1, during the treatment period (including periods of treatment
             interruption), and for at least 18 months after the last dose of study treatment

          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures and agreement to refrain from donating sperm for at least 3
             months after the last dose of study treatment

        Exclusion Criteria:

          -  Grade 3b follicular lymphoma

          -  History of transformation of indolent disease to diffuse large B-cell lymphoma (DLBCL)

          -  Known CD20-negative status at relapse or progression

          -  Central nervous system lymphoma or leptomeningeal infiltration

          -  Prior allogeneic stem-cell transplantation (SCT)

          -  Completion of autologous SCT within 100 days prior to Day (D) 1 of Cycle (C) 1

          -  Prior standard or investigational anti-cancer therapy as specified in protocol

          -  History of resistance to lenalidomide or response duration of &lt;1 year

          -  Treatment with systemic immunosuppressive medications

          -  History of solid organ transplantation

          -  Clinically significant toxicity from prior therapy that has not resolved to Grade &lt;=2
             (according to the National Cancer Institute Common Terminology Criteria for Adverse
             Events [NCI CTCAE], v4.0) prior to Day 1 of Cycle 1

          -  History of erythema multiforme, Grade &gt;= 3 rash, or blistering following prior
             treatment with immunomodulatory derivatives such as thalidomide and lenalidomide

          -  Active bacterial, viral, fungal, or other infection

          -  Positive for hepatitis B surface antigen (HBsAg), total hepatitis B core antibody
             (HBcAb), or hepatitis C virus (HCV) antibody at screening

          -  Known history of HIV positive status

          -  History of progressive multifocal leukoencephalopathy

          -  History of autoimmune disease

          -  Contraindication to treatment for TE prophylaxis

          -  Grade &lt;= 2 neuropathy

          -  History of other malignancy that could affect compliance with the protocol or
             interpretation of results

          -  Evidence of any significant, uncontrolled concomitant disease

          -  Inadequate hematologic function (unless due to underlying lymphoma)

          -  Abnormal laboratory values (unless due to underlying lymphoma)

          -  Pregnant or lactating or intending to become pregnant during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Medical Plaza II</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center; Hematology/Oncology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor; 51 Av Mal Lattre De Tassigny</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - Saint ELOI</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - HÃ´tel Dieu hematolgie clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud; Hematolgie</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hopital de Pontchaillo</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

